ADAM17 overexpression is associated with poorer clinical outcomes in cancer patients: a systematic review and meta-analysis

XuFeng Peng; Bo Hao; Nailong Cao; Jihong Wang; Xiangguo Lv; XinRu Zhang

doi:10.18632/oncotarget.23999

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Meta-Analysis:

ADAM17 overexpression is associated with poorer clinical outcomes in cancer patients: a systematic review and meta-analysis

XuFeng Peng, Bo Hao, Nailong Cao, Jihong Wang, Xiangguo Lv and XinRu Zhang _

PDF | HTML | How to cite

DOI pending

Metrics: PDF 412 views | HTML 479 views | ?

Abstract

XuFeng Peng1,*, Bo Hao3,*, Nailong Cao1, Jihong Wang1, Xiangguo Lv2 and XinRu Zhang1

1Department of Urology, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai 200233, China

2Department of Urology and Andrology, Shanghai Renji Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai 200001, China

3Department of Cardiothoracic Surgery, The Third Affiliated Hospital of Soochow University, Changzhou 213003, China

*These authors have contributed equally to this work

Correspondence to:

XinRu Zhang, email: [email protected]

Xiangguo Lv, email: [email protected]

Keywords: ADAM17; cancer; prognosis; lymph node metastasis; distant metastasis

Received: July 15, 2017 Accepted: December 26, 2017 Published: January 02, 2018

ABSTRACT

ADAM17 (a disintegrin and metalloproteinase 17) is overexpressed in many types of cancer, and its high expression in cancer patients is associated with increased risk of metastasis and a poorer prognosis. However, the clinical value of ADAM17 as a tumor biomarker remains largely unknown. In this meta-analysis, we investigated the relationships between ADAM17 levels, cancer metastasis, and patient prognosis. Twelve eligible studies involving a total of 1816 patients were identified in searches of the PubMed, Embase, Cochrane, and Chinese National Knowledge Infrastructure databases. Analysis of these studies revealed that ADAM17 overexpression is positively associated with lymph node metastasis in a fixed effect model and distant metastasis in a random effect model. Moreover, high ADAM17 expression was predictive of shorter overall and progression-free survivalof cancer patients in fixed effect models. These results suggest that ADAM17 maybe a useful biomarker for predicting metastasis and prognosis in cancer patients and may also aid in risk stratification and selection of individualized treatments.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 23999

Publication Alerts

Meta-Analysis:

ADAM17 overexpression is associated with poorer clinical outcomes in cancer patients: a systematic review and meta-analysis

Abstract